Physician profile
Wesley Matthew Smith
NPI 1316472525
$5,341.61
in general payments reported to CMS, 2019-2025
38 companies · $3,669 in 2025
The $3,669 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2021: $287 · 2022: $545 · 2023: $89.63 · 2024: $620 · 2025: $3,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,959 · Consulting Fee: $1,300 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,959.36 |
| Consulting Fee | $1,300.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,676.50 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $330.04 | 2024-2025 | Calquence, Lynparza, Imfinzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.81 | 2025 | |
| Novartis Pharmaceuticals Corporation | $232.84 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $232.61 | 2023-2025 | Opdivo, Opdualag |
| Lilly USA, LLC | $214.30 | 2022 | |
| Daiichi Sankyo INC. | $204.08 | 2024-2025 | Enhertu, Datroway |
| Beigene USA, INC. | $202.90 | 2024-2025 | Brukinsa, Tevimbra |
| Seagen INC. | $199.98 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $182.39 | 2019-2021 | |
| Kite Pharma, INC. | $149.05 | 2025 | Yescarta |
| Incyte Corporation | $137.52 | 2021-2025 | Jakafi |
| Medtronic, INC. | $131.07 | 2022 | |
| Glaxosmithkline, LLC. | $129.46 | 2025 | Blenrep, Ojjaara, Jemperli |
| Janssen Biotech, INC. | $116.43 | 2021-2024 | Akeega, Balversa, Erleada |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.